| Catalog No. | DB714018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 0.156 μg/ml |
|---|
| Range | 0.31-5 μg/mL |
|---|
| Accession | P26951 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
|---|
| Specifications | Talacotuzumab |
|---|
| Alternate Names | CSL-362-AML, CSL362, JNJ-56022473, CAS: 1826831-79-1 |
|---|
| Background | Talacotuzumab (TAL, JNJ-56022473) is an IgG1 monoclonal antibody targeting CD123 preferentially via antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells and has been shown to induce potent in vitro ADCC against IL3RA-expressing AML blasts/LSC and to reduce leukemic cell growth in murine xenograft models of human AML. In addition, the antibody inhibits signaling by IL-3, the main ligand of CD123, to reduce the proliferation of leukemic progenitor cells. |
|---|
| Note | For Research Use Only. |
|---|
